Erasca's Enterprise Value for the quarter that ended in Dec. 2023 was $66.12 Mil.
Erasca's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-141.53 Mil. Erasca's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2023 was -212.77%.
The historical rank and industry rank for Erasca's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
ERAS'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -10000 Med: 0 Max: 0
Current: -666.67
ERAS's Earnings Yield (Joel Greenblatt) % is ranked worse than 97.99% of 1394
companies
in the Biotechnology industry
Industry Median: -15.91
vs ERAS: -666.67
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Erasca's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2023 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Erasca Earnings Yield (Joel Greenblatt) % Historical Data
The historical data trend for Erasca's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Erasca's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Erasca Earnings Yield (Joel Greenblatt) % Distribution
For the Biotechnology industry and Healthcare sector, Erasca's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Erasca's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Erascas Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2023 is calculated as
Erasca's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-141.53 Mil.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Erasca Earnings Yield (Joel Greenblatt) % Related Terms
Thank you for viewing the detailed overview of Erasca's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ERAS has been successfully added to your 